Adjunct Aripiprazole for Symptomatic Hyperprolactinemia in Female Schizophrenia
阿立哌唑辅助治疗女性精神分裂症症状性高催乳素血症
基本信息
- 批准号:8310920
- 负责人:
- 金额:$ 30.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-02 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAgonistAmantadineAmenorrheaAntipsychotic AgentsAnxietyAreaBiological AssayBiological MarkersBone DensityBromocriptineConsensusCost AnalysisCosts and BenefitsDataDistressDopamineDopamine AgonistsDopamine AntagonistsDoseDouble-Blind MethodEstrogensEvidence based treatmentFemaleFundingGenderGonadal Steroid HormonesGynecomastiaHormonalHyperprolactinemiaIndividualInterventionKnowledgeMeasuresMediator of activation proteinMenstruationMental HealthMental disordersMissionModelingNational Institute of Mental HealthNew AgentsOligomenorrheaOutcomePatientsPerceived quality of lifePersonal SatisfactionPharmaceutical PreparationsPlacebosPopulationProgesteroneProlactinQuality of lifeRandomizedRecoveryRegimenRelative (related person)ReportingResearchResearch DesignResolutionRisperidoneSchizophreniaSedation procedureSex CharacteristicsSex FunctioningSexual DysfunctionSymptomsTestingTimeTreatment EffectivenessWeight GainWomanWorkaripiprazolebone healthbone turnovercontrol trialcostdepressive symptomsdesignevidence based guidelinesexperienceimprovedinnovationmedication complianceresearch studyresponsesex
项目摘要
DESCRIPTION (provided by applicant): Risperidone is available generically and one of the most widely used antipsychotic medications; but is associated with elevated prolactin. This elevation is particularly pronounced in women and most recent studies show that the vast majority of women have elevated prolactin levels with approximately 50% also having the corresponding side effects of amenorrhea, oligomenorrhea or galactorrhea. Elevated prolactin may be associated with sexual dysfunction, decreased quality of life, medication nonadherence and decreases in bone mineral density over time. Lowering the dose or switching medications due to this side effect in stabilized patients is not a practical option in most cases. There is little evidence to guide treatment in this important area however dopamine agonists such as bromocriptine or amantadine may exacerbate symptoms, have lacking efficacy data and are associated with side effects. We have sizeable pilot data to suggest that a low dose of aripiprazole (10 mg/day), a dopamine partial agonist, added to Risperidone can improve symptomatic prolactin side effects. We will complete a double blind randomized 16-week control trial examining adjunct aripiprazole (10 mg/day with increase to 15 mg/day at 8 weeks if no response) vs. placebo in 70 women with symptomatic hyperprolactinemia and hypothesize it will be effective in the resolution of amenorrhea, oligomenorrhea and galactorrhea. We also hypothesize that aripiprazole will significantly improve quality of life, personal well-being and sexual function. And, we will examine improvements in positive, negative and depressive symptoms, sex hormone levels and measures of bone turnover. The significance and innovation of this application is high as this is a significant complaint and concern of women and very little evidence is available to guide treatment in women who are stabilized and doing well on antipsychotic treatments but develop these significant side effects. If funded, this important treatment research study of adjunct aripiprazole treatment will provide invaluable data and treatment options for thousands of women who suffer from schizophrenia and will help move the field towards better tailoring and personalizing antipsychotic treatment, particularly for women who suffer from these problems.
描述(由申请人提供):利培酮是一种通用的抗精神病药物,是最广泛使用的抗精神病药物之一,但与催乳素升高有关。这种升高在女性中尤其明显,最近的研究表明,绝大多数女性的催乳素水平升高,约50%的女性还具有闭经、月经过少或乳汁过多的相应副作用。催乳素升高可能与性功能障碍、生活质量下降、药物不依从和骨密度随时间降低有关。在大多数情况下,由于稳定患者的这种副作用而降低剂量或转换药物并不是一个实际的选择。在这一重要领域,几乎没有证据指导治疗,但多巴胺激动剂如溴隐亭或金刚烷胺可能会加重症状,缺乏疗效数据,并与副作用有关。我们有相当大的试点数据表明,低剂量阿立哌唑(10毫克/天),多巴胺部分激动剂,添加到利培酮可以改善症状性催乳素副作用。我们将完成一项为期16周的双盲随机对照试验,在70名有症状的高泌乳素血症女性中检查辅助阿立哌唑(10 mg/天,如果无应答,则在8周时增加至15 mg/天)与安慰剂的对比,并假设其在闭经、月经过少和乳汁过多的解决方面有效。我们还假设阿立哌唑将显着改善生活质量,个人幸福和性功能。并且,我们将检查阳性,阴性和抑郁症状,性激素水平和骨转换措施的改善。该应用的重要性和创新性很高,因为这是女性的重大投诉和关注,并且很少有证据可用于指导稳定且抗精神病药物治疗效果良好但出现这些显著副作用的女性的治疗。如果获得资助,这项重要的阿立哌唑辅助治疗研究将为数千名患有精神分裂症的女性提供宝贵的数据和治疗选择,并将有助于将该领域推向更好的定制和个性化抗精神病治疗,特别是对于患有这些问题的女性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEANNA L KELLY其他文献
DEANNA L KELLY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEANNA L KELLY', 18)}}的其他基金
4/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
4/7 氯氮平预防精神分裂症暴力:一项随机临床试验
- 批准号:
10442519 - 财政年份:2021
- 资助金额:
$ 30.7万 - 项目类别:
4/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
4/7 氯氮平预防精神分裂症暴力:一项随机临床试验
- 批准号:
10655401 - 财政年份:2021
- 资助金额:
$ 30.7万 - 项目类别:
4/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
4/7 氯氮平预防精神分裂症暴力:一项随机临床试验
- 批准号:
10192468 - 财政年份:2021
- 资助金额:
$ 30.7万 - 项目类别:
A Randomized Controlled Trial of a Telementoring Program, Project ECHO, to increase Clozapine Prescribing
远程指导计划 ECHO 项目的随机对照试验,以增加氯氮平处方
- 批准号:
10088483 - 财政年份:2020
- 资助金额:
$ 30.7万 - 项目类别:
A Randomized Controlled Trial of a Telementoring Program, Project ECHO, to increase Clozapine Prescribing
远程指导计划 ECHO 项目的随机对照试验,以增加氯氮平处方
- 批准号:
10524766 - 财政年份:2020
- 资助金额:
$ 30.7万 - 项目类别:
A Randomized Controlled Trial of a Telementoring Program, Project ECHO, to increase Clozapine Prescribing
远程指导计划 ECHO 项目的随机对照试验,以增加氯氮平处方
- 批准号:
10305630 - 财政年份:2020
- 资助金额:
$ 30.7万 - 项目类别:
Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia
氯氮平治疗良性种族中性粒细胞减少症的生物标志物及安全性研究
- 批准号:
9514238 - 财政年份:2015
- 资助金额:
$ 30.7万 - 项目类别:
Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia
氯氮平治疗良性种族中性粒细胞减少症的生物标志物及安全性研究
- 批准号:
9179487 - 财政年份:2015
- 资助金额:
$ 30.7万 - 项目类别:
Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia
氯氮平治疗良性种族中性粒细胞减少症的生物标志物及安全性研究
- 批准号:
9293366 - 财政年份:2015
- 资助金额:
$ 30.7万 - 项目类别:
Adjunct Aripiprazole for Symptomatic Hyperprolactinemia in Female Schizophrenia
阿立哌唑辅助治疗女性精神分裂症症状性高催乳素血症
- 批准号:
8687741 - 财政年份:2011
- 资助金额:
$ 30.7万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 30.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 30.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 30.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




